Quantity label
1,000 mg; bottle volume not established
Quarterly text
Save $125.82; exact invoice needs confirmation
Formulation
Confirm prescribed concentration and pharmacy

A separate nasal listing with its own price

Trava lists NAD+ nasal spray at $157.91 monthly. The page describes a needle-free route within provider-guided care and shows a 1,000 mg label. We review it independently from the brand's injection because price, formulation and delivery are product-specific, even when the two offers share the same total-quantity wording.

The public description does not establish a bottle volume or complete dispensing specification. Ask which pharmacy supplies the product, what concentration is prescribed and how much is delivered. A total amount alone cannot establish the expected number of uses, the supply period or equivalence to a vial sold under another plan.

The quarterly offer needs a written breakdown

The page also says Save $125.82 with a quarterly-package label. That language does not clearly identify the actual quarterly payment. A reader should not assume the figure is the monthly price of that selection or subtract it from a three-month total without confirmation of what the provider intends.

Request an invoice showing the selected plan, initial charge, quantity and renewal timing. Compare it with the documented $157.91 monthly option only after the terms are clear. The lower-looking figure may represent a different commitment, and cancellation of another renewal may not create a refund for a supply already prepared or delivered.

What convenience does and does not establish

Nasal delivery avoids a needle, which is a practical feature of the route. It does not independently establish better absorption, brain-related effects or clinical equivalence to injections and IV services. We did not verify those comparisons for this finished Trava preparation, and the biological importance of NAD+ cannot fill that evidence gap.

Ask the clinician what supports the proposed use and what alternatives might address the same concern. The site identifies compounded medications as not FDA-approved. That status remains relevant even when a treatment is prescribed or a pharmacy follows quality standards; prescribing and product approval answer different questions.

Plan for the complete order and follow-up

Clarify whether assessment, delivery, ongoing support and any required testing are included in the monthly amount. The product page's brief description is not a complete itemized care agreement. Obtain the appropriate contact for routine clinical questions and product concerns rather than interpreting general service promises as a measured response-time guarantee.

The pharmacy should provide storage instructions and a beyond-use date for the bottle actually dispensed. Confirm the procedure for a damaged or delayed shipment before fulfillment. This nasal offer contributes a documented monthly price to the comparison, but its most useful next step is a specific bottle-and-billing quote. The $157.91 figure should remain attached to that limited public basis, without invented quarterly arithmetic or an assumed treatment outcome.

Sources & further reading

Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.

  1. Trava: NAD+ nasal spray offer Provider
  2. Trava: care model and compounding disclosure Provider
  3. FDA: Compounding questions and answers Regulator